Navigation Links
diaDexus, Inc. Reports 2012 First Quarter Financial Results

SOUTH SAN FRANCISCO, Calif., May 8, 2012 /PRNewswire/ -- diaDexus, Inc. (OTC Bulletin Board: DDXS), a company focused on the development and commercialization of proprietary cardiovascular diagnostic products, today announced financial results for the first quarter of 2012.

Total revenues for the first quarter of 2012 were $4.9 million, a 49% increase over $3.3 million for the first quarter of 2011, marking seven consecutive quarters of year-over-year revenue growth.  Total operating expenses for the quarter were $6.2 million, slightly more than the first quarter of 2011 due to higher product costs to support increased sales. The company's net loss for the quarter narrowed to $1.3 million from a $2.5 million net loss in the first quarter of 2011. The improvement in net loss for the quarter was largely due to greater sales of our PLAC® ELISA kits in the United States. Net cash used in operating activities for the first quarter of 2012 was $0.8 million versus $1.9 million for the same period the year prior. Cash and investments at March 31, 2012 were $15.9 million compared to $17.2 million at December 31, 2011.

diaDexus maintained its guidance for 2012 total revenues at $20 to $21 million and left unchanged its projected cash use in operations at approximately $6 million  for 2012. Future financing needs will depend on the company's ability to continue increasing the rate of adoption for the company's products by physicians and the company's progress in achieving additional positive coverage decisions from insurers for the PLAC® Test.

"Our first quarter revenues reflect increased market acceptance of the PLAC® Test.  diaDexus is poised to take advantage of continued growth in cardiovascular specialty laboratories, with over 80% of our revenues coming from this rapidly growing segment.  We are seeing more and more physicians understanding the value of advanced cardiovascular risk profiling for reducing and preventing cardiac and stroke events.  Our PLAC® Test ELISA Kit is becoming an integral part of these very important diagnostic tests," said Brian Ward, Ph.D., diaDexus' Chief Executive Officer.

diaDexus will host a webcast on Tuesday, May 8 at 1:15 PM PDT (4:15 PM EDT) to discuss the 2012 first quarter results. The webcast may be accessed via the company's website at

About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, is focused on the development and commercialization of proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for Lp-PLA2 Activity on-site. For more information, please visit the company's website at

Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products and other statements that are not historical in nature, particularly those that use terminology such as "will," "potential", "could," "can," "believe," "intends," "continue," "plans," "expects," "estimates" or comparable terminology. Forward-looking statements are based on current expectations and assumptions, and entail various known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to diaDexus that could cause actual results to differ materially from those expressed in such forward-looking statements include diaDexus' ability to submit a new 510(k) application for, and obtain FDA clearance of, its new automated Lp-PLA2 Activity test; diaDexus' ability to gain acceptance of its PLAC® Test products in the marketplace, including its ability to demonstrate that treatment of individuals based on their Lp-PLA2 levels improves clinical outcomes in prospective clinical studies; diaDexus' high degree of customer concentration, including the downward pressure that its largest customers may be able to exert on its product pricing; diaDexus' relationship with key customers, including GlaxoSmithKline, the licensor of Lp-PLA2; diaDexus' reliance on a sole source third party manufacturer to manufacture and supply diaDexus' PLAC® Test ELISA Kit; third party payors' acceptance of and reimbursement for the PLAC® Tests; diaDexus' ability to develop and commercialize new products and services; various risks associated with the international expansion of diaDexus' business; diaDexus' ability to successfully launch and commercialize the PLAC® Test for Lp-PLA2 Activity in Europe, and its dependence on its distributors for foreign sales of that test; diaDexus' ability to initiate and continue to manufacture the PLAC® Test for Lp-PLA2 Activity at its facility in South San Francisco, California; the adequacy of diaDexus' intellectual property rights; diaDexus' ability to satisfy its obligations under its license agreements, to maintain its license rights under those license agreements and to enter into any necessary licenses on acceptable terms; diaDexus' ability to attract, retain and motivate qualified personnel; the effects of U.S. and foreign government regulations and diaDexus' ability to comply with such regulations; diaDexus' limited revenue and cash resources; and diaDexus' significant corporate expenses, including real estate lease liabilities and expenses associated with being a public company. Additional factors that could cause diaDexus' results to differ materially from those described in the forward-looking statements can be found in diaDexus' most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and other reports filed with the Securities and Exchange Commission, and available at the SEC's web site at The information set forth herein speaks only as of the date hereof, and diaDexus disclaims any intention and does not assume any obligation to update or revise any forward looking statement, whether as a result of new information, future events or otherwise.-- Tables to follow --




(unaudited)Three Months Ended

March 31,20122011Revenues:License revenue$


76Royalty revenue1,0371,005Product sales3,8302,240Total revenues4,9433,321Operating costs and expenses:Product costs1,7191,132Sales and marketing1,1821,107Research and development1,2921,492General and administrative1,9762,114Total operating costs and expenses6,1695,845Loss from operations(1,226)(2,524)Interest income, interest expense and other income (expense), net:Interest income717Interest expense(101)—Other income (expense), net(3)—Loss before income tax(1,323)(2,507)Income tax provision(3)(3)Net loss$


(2,510)Basic and diluted net loss per share:$


(0.05)Weighted average shares used in computing basic and diluted net loss per share53,067,04553,067,057DIADEXUS, INC.CONDENSED BALANCE SHEETS(In thousands)March 31,2012December 31,2011(unaudited)AssetsCurrent assets:Cash and cash equivalents$


10,484Short-term investment securities3,7166,492Accounts receivable 2,3412,408Inventories163117Restricted cash400400Assets held for sale304304Prepaid expenses and other current assets799975Total current assets19,92621,180Long-term investments—250Restricted cash1,4001,400Property and equipment, net1,4851,350Other long-term assets150175Total assets$


24,355Liabilities and Stockholders' Equity Current liabilities:Accounts payable$


882Notes payable, current portion790372Deferred revenues, current portion342331Unfavorable lease obligations515492Accrued and other current liabilities2,0532,469Total current liabilities4,9814,546Non-current portion of notes payable4,1194,526Non-current portion of deferred revenue454530Non-current portion of deferred rent290266Non-current portion of unfavorable lease obligation2,9213,063Other long term liabilities301284Total liabilities13,06613,215Stockholders' equity:Preferred stock——Common stock531531Additional paid-in capital205,634205,557Accumulated other comprehensive loss(1)(5)Accumulated deficit (196,269)(194,943)Total stockholders' equity 9,89511,140Total liabilities and stockholders' equity$



SOURCE diaDexus, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. diaDexus, Inc. Adds Two New Directors; Corporate Overview & 3Q Results Webcast Set for November 16, 2010
2. diaDexus, Inc. Reports 2010 Third Quarter Financial Results
3. diaDexus, Inc. Reports 2011 First Quarter Financial Results
4. diaDexus, Inc. Reports 38% Year-Over-Year Revenue Growth for 2011 Third Quarter
5. diaDexus, Inc. to Host Webcast March 15, 2012 on 2011 Fourth Quarter and Year-End Financial Results
6. diaDexus, Inc. Reports 2011 Fourth Quarter and Year-End Financial Results
7. diaDexus, Inc. Highlights Findings from Two Outcomes Studies for its PLAC Lp-PLA(2) Activity Assay
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. Spherix Reports Second Quarter Earnings
10. Tapestry Reports Second Quarter 2007 Results
11. Callisto Reports on Second-Quarter 2007 Milestones
Post Your Comments:
(Date:10/9/2015)... , Oct. 9, 2015  Hi-Tech Pharmaceuticals ("Hi-Tech"), ... Contract Manufacturing, and iForce Nutrition ("iForce"), one of the ... United States , today announced that they ... Hi-Tech has agreed to acquire iForce. The transaction ... expand its distribution through iForce,s strong distribution network. ...
(Date:10/9/2015)... Eli Lilly and Company (NYSE: LLY ) ... 50 new jobs to its research and development presence at ... New York . --> ... include a translational immuno-oncology hub and a Lilly "portal," which ... to cutting-edge drug discovery capabilities, including chemistry and lead optimization ...
(Date:10/9/2015)... 9, 2015 Ansun BioPharma announced a presentation ... America ) regarding the compassionate use of DAS181 under ... respirator who was co-infected with influenza and parainfluenza (Abstract ... therapy, O 2 requirement was reduced and the ... to go off the respirator on day 5. Between ...
Breaking Medicine Technology:
... MINNEAPOLIS, Jan. 19, 2012 Zyga Technology, Inc. announced ... the company and will serve as Vice President of ... (Logo: ) Joe ... Medical Device Industry.  He began his career at Codman ...
... Berkery Noyes, an independent middle market investment bank, today ... trend report for the Pharma & Healthcare ... report analyzes the sector for 2011 and compares it ... includes information and technology companies servicing pharmaceutical, healthcare payer, ...
Cached Medicine Technology:
(Date:10/10/2015)... York, NY (PRWEB) , ... October 10, 2015 , ... ... some alarming numbers on the growth of cybercrime costs for US companies. The New ... on Tuesday, October 6th. With averages showing increases hovering around 20% among the companies ...
(Date:10/10/2015)... , ... October 10, 2015 , ... Isabel Healthcare will ... , On the heels of the release of the Institute of Medicine’s latest report ... their integration with Cerner solutions that assist healthcare providers and consumers to potentially reduce ...
(Date:10/9/2015)... ... October 09, 2015 , ... The American Osteopathic ... for Graduate Medical Education J. Michael Finley, DO, as the recipient of the ... for his impact on graduate medical education opportunities for osteopathic residents, and his ...
(Date:10/9/2015)... ... 2015 , ... A new health tool that helps identify if a sore ... ) – just in time for the cold and flu season, which the ... many in the U.S., the real start of cold/flu season is the start of ...
(Date:10/9/2015)... ... October 09, 2015 , ... Dentist in Huntington ... orthodontic system that uses clear, plastic aligners. This alternative to braces has become ... which allow patients to complete treatment in privacy. Additionally, Invisalign aligners are removable, ...
Breaking Medicine News(10 mins):
... a significant decrease in the function of the serotonin system ... that regulates such functions as impulse control and mood. It ... men. This is the conclusion of multidisciplinary research carried out ... the University of Gothenburg, Sweden. The research group in ...
... , TUESDAY, Nov. 15 (HealthDay News) -- ,Elite female marathon ... and sedentary women, a new study finds. This type ... the most common type of heart disease and the leading ... recent Minneapolis Heart Institute study found that elite male marathoner ...
... specific community-based screening may increase awareness of the dangers of ... in the November 2011 issue of Otolaryngology-Head and Neck ... 60 to 80% of head and neck cancers could be ... national programs to date have had little impact reducing these ...
... Human pluripotent stem cells, which can develop into any ... or sugar fermentation, to drive their metabolic activities. ... depend more on cell mitochondria to convert sugar and ... energy-producing process called oxidative phosphorylation for their metabolic needs. ...
... clear links between erectile dysfunction (ED) and peripheral neuropathy, according ... journal BJUI . "Up to now the impact ... has been underestimated" says lead author Dr Consuelo ,Valles-Antua, from ... Asturias in Oviedo. "However our study of 90 ...
... HealthDay Reporter , MONDAY, Nov. 14 (HealthDay News) ... contraceptive pill over the past 40 years, the amount of ... the increased incidence of prostate cancer around the world, Canadian ... cancers, and the widespread use of the pill might raise ...
Cached Medicine News:
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
For the quantitative in vitro determination of Aspartate Aminotransferase (AST) in serum and plasma....
Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....
Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...
Medicine Products: